DotLab
DotLab is a women's healthcare technology company that has developed DotEndo, a first-of-its-kind non-invasive blood test using microRNA biomarkers and machine learning to diagnose endometriosis, currently available to select US healthcare providers including gynecologists and reproductive endocrinologists.
- Company typePrivate
- Founded2017
- HeadquartersBranford, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What DotLab does
DotLab (Dot Laboratories, Inc.) is a women's healthcare technology company founded in 2016-2017 by CEO Heather Bowerman, headquartered in San Francisco, California, with a clinical laboratory in Branford, Connecticut. The company develops and commercializes diagnostic tests for endometriosis, a condition affecting approximately 200 million women globally and historically requiring laparoscopic surgery for diagnosis. DotLab's sole commercial product, DotEndo, is a non-invasive blood test that applies proprietary machine learning algorithms to differential expression levels of endometriosis-specific microRNA biomarkers to deliver a dichotomous diagnostic result via a physician portal within approximately ten days. The test demonstrated high accuracy (AUC 0.94) in clinical validation published in the American Journal of Obstetrics & Gynecology and is supported by ongoing data collection through the EMPOWER Study, a multi-center cohort study enrolling approximately 750 participants across nine leading US academic medical centers.
DotLab operates as a clinical laboratory services business, generating revenue by performing the DotEndo test on blood samples ordered by healthcare providers. Distribution is exclusively B2B through gynecologists, reproductive endocrinologists, and endometriosis specialists, with patient specimens collected in-clinic or via direct-to-patient mail-in kits and processed at the company's CLIA-compliant laboratory in Branford. The company launched DotEndo commercially in 2021 on a limited basis to select healthcare providers and is in the early stages of broader market access expansion. Pricing is not publicly disclosed and is determined through healthcare system negotiations and insurance coverage pathways.
The company is venture-backed, having raised approximately $12.65 million across disclosed rounds, including a $10 million Series A in July 2019 led by strategic investor CooperSurgical (a Cooper Companies business unit) with participation from Tiger Global Management, Luxor Capital Group, and Wilson Sonsini Goodrich & Rosati, and a subsequent round in 2023 with Kapor Capital and Inclusive Ventures Lab. DotLab holds exclusive worldwide intellectual property rights for its microRNA endometriosis diagnostic technology and maintains HIPAA, HITECH, and CCPA compliance. Recognition includes the 2019 FierceMedTech Fierce 15 designation and a 2018 Readers' Digest Top Medical Breakthrough award.
DotLab firmographics
Firmographics- Name
- DotLab
- Legal name
- Dot Laboratories, Inc.
- Website
- https://dotlab.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DotLab is a women's healthcare technology company that has developed DotEndo, a first-of-its-kind non-invasive blood test using microRNA biomarkers and machine learning to diagnose endometriosis, currently available to select US healthcare providers including gynecologists and reproductive endocrinologists.
- Ownership category
- akta.pro rank
DotLab industry classification
Industry- Product category
- Endometriosis Diagnostic Testing
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industry
- Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)
Keywords
Where DotLab is headquartered
LocationHeadquarters
- HQ city
- Branford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
DotLab business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: DotLab generates revenue through its diagnostic laboratory test service. Healthcare providers order DotEndo tests which are performed in DotLab's clinical laboratory. The test involves blood sample collection, analysis using proprietary microRNA biomarker technology, and delivery of results through a physician portal within ten days.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
DotLab product offering
Product offeringCore offering
DotLab develops and provides DotEndo, a first-of-its-kind non-invasive blood test for the diagnosis of active endometriosis. The test analyzes proprietary microRNA biomarkers in a blood sample using a machine learning algorithm to deliver a dichotomous positive/negative result through a physician portal within approximately ten days, addressing a diagnostic gap historically requiring laparoscopic surgery.
Product overview
DotLab is a women's healthcare technology company offering a single core product: DotEndo, a breakthrough non-invasive blood test for endometriosis diagnosis. DotEndo analyzes microRNA biomarkers in blood samples using a proprietary algorithmic approach to provide actionable diagnostic results, addressing a significant gap in women's healthcare where diagnosis has traditionally required invasive laparoscopic surgery.
Differentiator
Problem solved
Functional benefit
Brands
- DotEndo: A breakthrough, non-invasive blood test that aids in the diagnosis of active endometriosis by measuring microRNA biomarkers in the blood.
Products and services
- DotEndo A first-of-its-kind non-invasive blood test that measures endometriosis-specific microRNA biomarkers and applies a proprietary multi-analyte algorithm to provide a positive/negative result indicating the presence or absence of active endometriosis. Designed to replace laparoscopic surgical diagnosis for healthcare providers (gynecologists, reproductive endocrinologists, endometriosis specialists) and to shorten the average 7-10 year diagnostic delay for their patients.
Quantifiable outcome
- AUC of 0.94 in clinical validation study for distinguishing endometriosis from other gynecologic pathologies
- +2 more outcomes
Companies that use DotLab
Customer profileSegments3 records
Ideal customer profiles1 record
DotLab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
DotLab partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Yale UniversitycoreDotLab partnered with researchers at Yale University to evaluate the performance of the test relative to laparoscopy in patients with and without endometriosis across multiple clinical cohorts. Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, serves as a key collaborator and advisor.
- EMPOWER Study Clinical SitescoreMulti-center collaboration with leading endometriosis centers across the US including: Academia of Women's Health and Endoscopic Surgery, MedStar Health, NewYork-Presbyterian/Columbia University Irving Medical Center, Penn Medicine, Penn State College of Medicine, Stanford Medicine, The Advanced Gynecologic Surgery Institute, University Hospitals in Cleveland, Ohio, and University of Pittsburgh Medical Center. These partnerships support the EMPOWER Study enrolling approximately 750 participants for clinical validation.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
DotLab competitors and assessment
Company assessmentDirect peers
- Aspira Women's Health: Direct peer focused on non-invasive women's health diagnostics, including ovarian cancer risk assessment. Comparable in business model (specialty lab offering biomarker-based tests to OB/GYNs) and target customer segment (gynecologists managing complex women's health conditions).
- Natera: Direct peer operating a specialty clinical lab that performs non-invasive molecular diagnostics on blood samples, including reproductive health and women's health tests. Comparable in proprietary biomarker + algorithmic approach, B2B clinician channel, and CLIA lab operating model.
Broad incumbents
- Myriad Genetics: Established molecular diagnostics incumbent with proprietary biomarker tests ordered by clinicians. Comparable in specialty lab business model and proprietary IP-driven test menu, though Myriad operates at much larger scale across multiple indications including women's health (BRCAtesting).
- Hologic: Large women's health-focused diagnostics and medical device company with deep OB/GYN distribution relationships. Comparable as a women's health diagnostics incumbent serving gynecologists, though Hologic's portfolio spans imaging, surgical, and screening diagnostics rather than specialty molecular tests.
- CooperSurgical: Global leader in women's health, fertility, and reproductive genomics, and DotLab's lead Series A investor. Comparable as the dominant distributor into the same OB/GYN and reproductive endocrinology channels DotLab targets, though CooperSurgical's core franchise is devices and IVF consumables rather than molecular diagnostics.
- Veracyte: Established genomic diagnostics company combining proprietary RNA-based biomarker technology with machine learning to develop specialty tests. Comparable in molecular biomarker + ML/algorithmic architecture and CLIA lab-based delivery model serving specialist physicians.
- LabCorp: Major clinical reference laboratory offering thousands of diagnostic tests including specialty women's health panels. Comparable as a clinical lab infrastructure provider, though LabCorp operates at vastly larger scale and breadth, and could be a future channel partner or competitive threat for DotEndo.
- Invitae: Genetic diagnostics company offering broad specialty molecular testing, including women's health and reproductive genetics. Comparable in proprietary diagnostic IP and B2B clinician-channel model, though Invitae operates across many indications with a focus on hereditary genetic testing.
Emerging players
- Progenity: Women's health and reproductive diagnostics company developing novel molecular tests. Comparable in addressing unmet diagnostic needs in reproductive health and use of novel biomarkers, though Progenity has historically focused on prenatal and gastrointestinal applications.
- Celmatix: Women's health biotech focused on reproductive medicine, including diagnostics and therapeutics for conditions like endometriosis and PCOS. Comparable in targeting endometriosis and unexplained infertility with novel biomarker/AI approaches, though Celmatix has expanded toward therapeutic development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DotLab social profiles
Digital presenceDotLab compliance and trust
Trust signalCompliance2 records
DotLab financial estimates
Financial estimateRevenue estimate
Valuation estimate
DotLab leadership team
Management profileNumber of profiles
Profiles1 record
DotLab funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DotLab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DotLab
What does DotLab do?
DotLab develops and provides DotEndo, a first-of-its-kind non-invasive blood test for the diagnosis of active endometriosis. The test analyzes proprietary microRNA biomarkers in a blood sample using a machine learning algorithm to deliver a dichotomous positive/negative result through a physician portal within approximately ten days, addressing a diagnostic gap historically requiring laparoscopic surgery.
Is DotLab a public or private company?
DotLab is a private company. It is classified as venture growth investor backed and is currently operating.
When was DotLab founded?
DotLab was founded in 2017. It employs 11 to 50 people.
Where is DotLab based?
DotLab is headquartered in Branford, United States, in the North America region.
How does DotLab make money?
One revenue line is on record: diagnostic Testing Services.
Who are DotLab's main competitors?
Direct peers on record are Aspira Women's Health and Natera. Broad incumbents are Myriad Genetics, Hologic, CooperSurgical, Veracyte, LabCorp and Invitae. Emerging players are Progenity and Celmatix.
Does DotLab have an API?
No public API is recorded for DotLab.
What industry is DotLab in?
DotLab's product category is Endometriosis Diagnostic Testing. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 621511 and its SIC code is 8071.